Study of Lanreotide Autogel 120mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
- 20 November 2024 - 1 mins read
The purpose of this extension study is to assess the long term safety of patients with neuroendocrine tumour, who are treated with lanreotide Autogel and who participated in a previous study, 2-55-52030-726.
20 November 2024
1 mins read
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
20 November 2024
1 mins read
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
20 November 2024
1 mins read
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
20 November 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
20 November 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Follow-on Study
20 November 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Study
20 November 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Study
20 November 2024
1 mins read
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
20 November 2024
1 mins read
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
20 November 2024
1 mins read